NeurAxis (NRXS) Expected to Announce Quarterly Earnings on Tuesday

NeurAxis (NASDAQ:NRXS) will likely be releasing its results before the market opens on Tuesday, May 12th. Analysts expect NeurAxis to post earnings of ($0.19) per share and revenue of $1.45 million for the quarter.

NeurAxis Price Performance

Shares of NRXS stock opened at $8.20 on Friday. The stock has a market capitalization of $94.34 million, a PE ratio of -4.46 and a beta of 1.50. NeurAxis has a 1-year low of $2.00 and a 1-year high of $9.33. The business has a 50-day moving average of $7.03 and a 200 day moving average of $4.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NRXS. Citadel Advisors LLC increased its position in NeurAxis by 39.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,627 shares of the company’s stock valued at $110,000 after buying an additional 10,103 shares in the last quarter. Manatuck Hill Partners LLC bought a new position in NeurAxis during the 2nd quarter valued at approximately $122,000. State Street Corp bought a new position in NeurAxis during the 4th quarter valued at approximately $139,000. Geode Capital Management LLC increased its position in NeurAxis by 48.8% during the 4th quarter. Geode Capital Management LLC now owns 75,653 shares of the company’s stock valued at $343,000 after buying an additional 24,817 shares in the last quarter. Finally, Rosalind Advisors Inc. bought a new position in NeurAxis during the 4th quarter valued at approximately $1,299,000. Institutional investors own 11.77% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Craig Hallum increased their target price on NeurAxis from $8.00 to $13.00 and gave the company a “buy” rating in a report on Friday, March 20th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, NeurAxis presently has an average rating of “Buy” and an average price target of $13.00.

NeurAxis Company Profile

NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.

NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.